#USA #New York #Pomerantz Law Firm #Galectin Therapeutics #NASDAQ GALT

Pomerantz Law Firm Investigates Galectin Therapeutics

Pomerantz LLP, a well-regarded law firm specializing in class action litigation, has begun an investigation on behalf of investors in Galectin Therapeutics Inc. (NASDAQ: GALT). The investigation is centered on allegations of potential securities fraud and unlawful business activities. Investors who may have been impacted are encouraged to reach out to Pomerantz for further guidance.

On December 19, 2025, Galectin held a meeting with the U.S. Food and Drug Administration (FDA) regarding its drug belapectin, which acts as a galectin-3 inhibitor. During this meeting, the FDA changed the format of Galectin's initial Type C meeting request from an in-person or telephonic discussion to a written response. Although the Company stated that they seek to proceed with a follow-up meeting to finalize their upcoming clinical trial, several critical parts of the trial design are still unresolved.

Following the news of this development, Galectin's stock price plummeted. It dropped by $1.78 per share, a staggering 28.9% decrease, finishing at $4.38 per share. This sharp fall raised flags among investors and prompted Pomerantz to take action, indicating that securities fraud may have occurred during the management of the company’s affairs.

With over 85 years of experience in securities class action litigation, Pomerantz has built a reputation for advocating for the rights of investors affected by corporate wrongdoing and securities fraud. The firm has successfully recovered numerous multimillion-dollar settlements for aggrieved investors, bolstering its role as a leading firm in this space.

In light of the recent troubling developments surrounding Galectin Therapeutics, investors may face significant challenges. Those who have stakes in GALT are advised to consider their legal options and act promptly to protect their interests.

Anyone who wishes to participate in this ongoing investigation can contact Danielle Peyton at Pomerantz for additional information, ensuring they have access to all potential remedies and avenues available to them.

For Galectin, the path ahead is critical as unanswered questions linger over trial design agreements with the FDA. Investors remain hopeful for clarity and resolution as the company aims to advance its clinical development programs. As the situation unfolds, Pomerantz Law Firm will keep investors informed about their rights and any opportunities for recourse that may emerge from this investigation.